Targeted activation of one's own immune system is a new therapeutic approach to cancer treatment in which the pharmaceutical industry is showing increasing interest. Our research groups developed new glycolipids as antigens. With this ConcepTT project we want to subject 3 analogues to in vitro ADME / Tox tests and an in vivo PK study (based on industry standards). An initial series of discussions with companies shows that this information is desirable for partnering, given the unusual glycolipid structure of these compounds. Positive pharmacological data would remove an industry risk and significantly strengthen the UGent valorization position of these leads.